Q-omics provides the consensus-scored HSP90AA6P profile across patient tissues and cancer cell-line models. HSP90AA6P expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HSP90AA6P is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, HSP90AA6P RNA expression shows 16,037 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where HSP90AA6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSP90AA6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSP90AA6P survival associations across molecular data types. HSP90AA6P RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSP90AA6P RNA expression–survival associations across cancer types. High HSP90AA6P expression shows unfavorable associations in UVM, BRCA, LUAD, UCEC and ESCA, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for HSP90AA6P RNA expression.
This table summarizes HSP90AA6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HSP90AA6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSP90AA6P shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUSC, BRCA, LUAD and LIHC. The KIRC box plot shows higher HSP90AA6P RNA expression in normal versus tumor tissue (log2 FC = −0.158, t-test p < 0.001).
This table shows molecular features associated with HSP90AA6P in patient tissues and cancer cell lines. In patient samples, HSP90AA6P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
